Focused Excellence.

What’s New for Insurers in Mental Health Parity Compliance

Federal and State Cannabis Rules Are Moving in Different Directions

Are Vaccine Passports the Key to Reopening?

Whistleblowing, Retaliation Risks Are On the Rise for Health Care Employers

American Rescue Plan Delivers New Stimulus Funding

President Biden’s Use of the Defense Production Act

COVID-19 Vaccines: The Ethical and Legal Challenges to Immunization

Congressional Health Care Legislative Agenda

Private Equity Investment in Risk-Bearing Provider Organizations

The Biden Administration’s First 100 Days

Forecast for Telehealth Fraud and Abuse Risk in 2021

Privacy Concerns When Contact Tracing in the Health Care Workplace

SCOTUS Watch: The ACA and Key Health Law Areas Justice Barrett Could Impact

On the Ballot 2020: Health Care Policy Outlook

Key Considerations for Reshoring U.S. Drug Manufacturing

Darren Black on The Future of Health Care: Health Care Delivery and Consolidation Trends in 2020 and Beyond

Product Launching in the Era of COVID-19

Carsten Beith on The Future of Health Care: Health Care Delivery and Consolidation Trends in 2020 and Beyond

Barry Ostrowsky on The Future of Health Care: Health Care Delivery and Consolidation Trends in 2020 and Beyond

Holding Pattern: Cannabis Industry Waits for FDA Regulatory Rulemaking

Second-Wave Contingency Planning and Risk Mitigation Strategies

Fraud and Abuse Enforcement Priorities in the Wake of COVID-19

The Impact of Revenue and Budget Shortfalls in Light of Coronavirus

Telehealth Flexibility: Key Regulatory Changes Impacting Providers During and Beyond the Coronavirus Pandemic

Partnering with a private equity (PE) investor can help physicians monetize the value of their practice.

Private equity investment in physician groups has steadily grown over the last several years, leaving some groups wondering, is PE for us? There are five critical factors to consider.

$3 billion recovered under the False Claims Act. That’s what the US Department of Justice reported collecting in FY2019.

Examining how the FDA’s approach is impacting innovation and product development in the medical device industry.

The risks companies face as the restrictions on the use of medical and recreational marijuana are relaxed.

Key employment law concerns that health care companies should address during a transaction.

Methods for tackling the many demands that in-house counsel face in today’s health care environment. 

Why due diligence is a critical step for investors when entering into a transaction with any company interacting in the health care space.

Legal implications and concerns arising from artificial intelligence (AI) in the health care and life sciences industry.

What the ongoing shift of Medicaid funding from the federal government to the states means for payors and providers.

Legal and regulatory trends driving business opportunities in the precision medicine industry.